69 results
8-K
EX-99.1
SGHT
Sight Sciences Inc
2 May 24
Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance
4:07pm
and uncertainties identified by management that could impact future results, which include, but are not limited to: changes in the reimbursement … environment, including coverage decisions and reimbursement rates; the outcome of clinical trials; the outcome of legal proceedings or regulatory matters
8-K
EX-99.2
SGHT
Sight Sciences Inc
7 Mar 24
Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance
4:15pm
and objectives; and the Company’s ability to obtain and maintain sufficient reimbursement for its products. These statements often include words … and equitable reimbursement Develop international markets TearCare® Access + Expansion Pursue coverage and equitable reimbursement Generate
8-K
EX-99.1
SGHT
Sight Sciences Inc
7 Mar 24
Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance
4:15pm
interventional glaucoma and dry eye technologies, make significant progress towards meaningful reimbursement for TearCare, and based on the productive start … , which include, but are not limited to: changes in the reimbursement environment, including coverage decisions and reimbursement rates; the outcome
8-K
im3ujfjb 3lhpnd
2 Feb 24
Departure of Directors or Certain Officers
4:02pm
8-K
EX-10.1
td037zaw9
23 Jan 24
Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules Capital
4:07pm
8-K
trv9o8dwvn
9 Nov 23
Other Events
5:06pm
8-K
EX-99.1
n8f 8gw56z338bi8h
7 Nov 23
Sight Sciences Reports Third Quarter 2023 Financial Results
4:20pm
8-K
EX-99.2
hbujv4hgars
7 Nov 23
Sight Sciences Reports Third Quarter 2023 Financial Results
4:20pm
8-K
fird 3s0i6xuypt6
26 Oct 23
Regulation FD Disclosure
5:24pm
8-K
y8s27 y0fdt16c4ytewy
17 Oct 23
Cost Associated with Exit or Disposal Activities
4:02pm
8-K
hnt e5azybzqut5gqk7
11 Sep 23
Sight Sciences Appoints Matt Link as Chief Commercial Officer
5:15pm
8-K
EX-99.2
tg1ggl gn
11 Sep 23
Sight Sciences Appoints Matt Link as Chief Commercial Officer
5:15pm
8-K
EX-99.2
s8ak m4iur18y5h07p
3 Aug 23
Sight Sciences Reports Second Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023
4:10pm
8-K
EX-99.1
3mdpe39no5m aefvc
8 May 23
Regulation FD Disclosure
4:46pm